Results 1 to 10 of about 1,844,033 (204)
Localized Scleroderma, Systemic Sclerosis and Cardiovascular Risk: A Danish Nationwide Cohort Study
Acta Dermato-Venereologica, 2017 Recent findings indicate that patients with systemic sclerosis have an increased risk of cardiovascular disease. To determine whether patients with systemic sclerosis or localized scleroderma are at increased risk of cardiovascular disease, a cohort ...
Jeanette Halskou Hesselvig +5 more
doaj +2 more sources
Pathophysiology of systemic sclerosis (scleroderma)
The Kaohsiung Journal of Medical Sciences, 2022 AbstractSystemic sclerosis (scleroderma) is an autoimmune‐triggered chronic fibrosing disease that affects the skin and many other organs. Its pathophysiology is complex and involves an early endothelial damage, an inflammatory infiltrate and a resulting fibrotic reaction.
Ann‐Helen Rosendahl +2 more
openaire +4 more sources
Pathogenesis of Scleroderma (Systemic Sclerosis)
Journal of Investigative Dermatology, 1982 Increasing interest in the vascular features of scleroderma has led to the hypothesis that the blood vessel is the major target tissue and that the endothelial cell is the principal cell target. Useful observations stemming from the vascular hypothesis include the use of microvascular abnormalities in the early detection of the patient destined to ...
E. LeRoy
openaire +4 more sources
Systemic sclerosis sine scleroderma [PDF]
Advances in Clinical and Experimental Medicine, 2017 Systemic sclerosis is a rare generalized disease with scleroderma, i.e. skin thickening as one of the most common symptoms. The disease has 2 main subsets, diffuse and limited forms. The subset known as systemic sclerosis sine scleroderma (ssSSc) is a very rare subset characterized by the total or partial absence of cutaneous manifestations of systemic
Magdalena Kopeć-Mędrek +1 more
openaire +4 more sources
Antiphospholipid Antibodies and Systemic Scleroderma
Turkish Journal of Hematology, 2013 Objective: Antiphospholipid antibodies (APLs) could be associated with an increased risk of vascular pathologies in systemic scleroderma. The aim of our study was to search for APLs in patients affected by systemic scleroderma and to evaluate their ...
Awa Oumar Touré +8 more
doaj +7 more sources
A rare cutaneous manifestation of systemic sclerosis [PDF]
European Journal of Case Reports in Internal MedicineA 43-year-old male with a history of intravenous drug use and alcohol consumption presented to the emergency department with three-month history of failure to thrive.
Joelle Sleiman +3 more
doaj +2 more sources
Systemic Scleroderma—Definition, Clinical Picture and Laboratory Diagnostics
Journal of Clinical Medicine, 2022 (1) Background: Scleroderma (Sc) is a rare connective tissue disease classified as an autoimmune disorder. The pathogenesis of this disease is not fully understood. (2) Methods: This article reviews the literature on systemic scleroderma (SSc).
Anna Kowalska-Kępczyńska
semanticscholar +1 more source
Arthritis Research & Therapy, 2023 Background The study of molecular mechanisms characterizing disease progression may be relevant to get insights into systemic sclerosis (SSc) pathogenesis and to intercept patients at very early stage.
Chiara Bellocchi +6 more
doaj +1 more source
Fibrosing arthropathy in juvenile scleroderma
Современная ревматология, 2021 The group of scleroderma diseases includes a number of clinical entities, the main symptom of which is skin tightening. Scleroderma is a prominent example of these diseases, characterized by excessive synthesis and deposition of collagen in organs and ...
D. A. Dibrov +2 more
doaj +1 more source
Localized scleroderma: clinical spectrum and therapeutic update [PDF]
Anais Brasileiros de Dermatologia, 2015 Scleroderma is a rare connective tissue disease that is manifested by cutaneous sclerosis and variable systemic involvement. Two categories of scleroderma are known: systemic sclerosis, characterized by cutaneous sclerosis ...
Mariana Figueiroa Careta, Ricardo Romiti
doaj +2 more sources